Choosing an addiction treatment business broker means trusting someone with the financial details, staff relationships, and reputation of a business you built around patient care. A polished presentation and a long buyer list tell you little about how that person will handle a difficult reimbursement question or an offer with uncertain financing. The useful test is concrete: what will the advisor do, who will do it, how will conflicts be handled, and what will you owe? Use those questions to compare proposals before you sign an exclusive engagement.
Business broker, M&A advisor, and investment banker describe overlapping services. The title alone does not establish the scope, staffing, or quality of an engagement. A small owner-operated program and a multisite organization may need different support. Start with your actual complexity: service lines, payer relationships, ownership structure, financial reporting, and the role you want after a transaction.
Ask each firm to describe its deliverables in writing. Will it help reconcile operating reports to financial statements, prepare marketing materials, build a targeted buyer list, manage questions, compare offers, and coordinate diligence? Identify what stays with your accountant, attorney, and clinical leadership. An advisor can organize these workstreams; it should not replace healthcare counsel or make clinical judgments.
Keep the interview focused on representation. If you need background on the broader transaction journey, the sister-site guide to selling an addiction treatment center covers that separately. Here, the decision is who can execute the assignment your business actually requires.
Ask for examples involving a comparable operating model. Experience with a residential facility may be useful, but an outpatient program with concentrated commercial payers raises different questions. Ask which team member handled the work, whether the advisor represented the seller, and which obstacles changed the transaction. An introduction to a buyer is different from leading an engagement through closing.
References should illuminate judgment. With the former client’s permission, ask how the advisor communicated unwelcome news, handled a buyer’s proposed price reduction, and protected management’s time. Ask what remained unresolved at signing and how it was addressed. Respect transaction confidentiality; a credible advisor should explain its role without disclosing another owner’s private financials.
Also ask how the firm satisfies any applicable registration or exemption requirements. FINRA BrokerCheck helps verify claimed securities registrations and disclosed history. However, the SEC describes a statutory exemption for qualifying M&A brokers, subject to conditions. Absence from BrokerCheck alone does not settle eligibility. Have counsel assess the proposed activities and applicable federal and state requirements.
A buyer database is a starting point. Ask the advisor how it will verify four things before giving a prospective acquirer access to sensitive information:
Request an outreach plan with reasons for including each buyer and a process for approving the list. The sister-site overview of treatment center buyers explains buyer categories. Your advisor’s job is to test the specific organizations behind those categories and report what is still unverified.
The engagement letter sets the working relationship long before a purchase agreement exists. Review it with counsel and resolve these five areas:
If multiple owners must approve the engagement or a sale, settle that authority now. The advisor should know who can instruct the team and which decisions require broader owner consent.
Ask to see a sample confidentiality workflow. It should address anonymous initial outreach, approval before identifying the business, buyer nondisclosure agreements, restricted data-room access, and a record of what was shared. Discuss competitor access separately. A local competitor may infer your identity from a combination of location, program size, and payer mix even without your company name.
Patient information needs a separate legal analysis. An NDA does not by itself authorize disclosure of protected records. Start with appropriately aggregated or de-identified operating information, and have privacy counsel determine what any later review permits. The HHS Part 2 fact sheet explains substance use disorder record protections and the February 16, 2026 compliance date for the updated rule. Those protections cannot be replaced by a transaction deadline.
Ask who may contact staff, referral sources, landlords, and payers, and at what stage. Require owner approval for those contacts. The advisor should coordinate with counsel on necessary notices and approvals while keeping management informed. Also agree how access will end and how retained information will be handled when a buyer leaves the process.
There is no useful comparison between two fee percentages until the calculation base and payment timing are clear. Ask each firm to show a written illustration using the same hypothetical offer, including:
These are questions to ask any addiction treatment M&A advisor, not statements of Olympic M&A’s engagement terms. Obtain the actual proposal. A low quoted fee can come with a narrower assignment; a higher fee does not establish better execution. Compare scope, incentives, and net seller proceeds under the same assumptions.
Meet the people who will write the materials and manage buyer questions. Ask about current workload, backup coverage, expected response times, and access to senior judgment when a difficult issue arises. Request a sample status report with confidential information removed. It should make unresolved decisions and next steps easy to see, rather than simply count calls and emails.
Agree on a regular reporting rhythm and escalation rules. You should know which buyers have signed NDAs, what feedback they provided, what information is outstanding, and which decisions need your attention. If the advisor recommends changing the process, ask for the evidence. Management should be able to keep running the treatment business without losing visibility into the transaction.
Give shortlisted firms the same limited, nonpatient business summary and a hypothetical offer. Ask how they would evaluate a financing condition, unclear rollover terms, and a request for lengthy exclusivity. Strong answers identify missing information, assign the right specialist, and explain what should be resolved before committing. An unconditional promise of a particular price or closing date deserves scrutiny. Evaluate written scope, comparable experience, conflict disclosures, communication, and total cost together. For the offer-stage questions, use addiction treatment center letter-of-intent terms. Select the advisor whose approach you understand and whose proposal makes accountability explicit.
Prepare a short summary of services, locations, ownership, approximate business size, payer mix, and your priorities. Leave patient records out. Ask the advisor to explain likely scope, team responsibilities, conflicts, and fees before you commit to representation. A useful first conversation should make the decision clearer even if you are not ready to launch.
Tony Siebel is the Founder and Managing Director of Olympic M&A. His background includes corporate development and physician-practice acquisitions at MDVIP, as well as serving as Vice President and Associate Partner at Stoneridge Partners, including work in its Behavioral Health Division.
Olympic M&A advises founders and healthcare business owners on transactions with private equity groups and strategic acquirers. Learn more about the firm’s behavioral health advisory services and discuss the scope of support appropriate for your business.
Contact Olympic M&A | info@olympicma.com | 502.360.8320